Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Frequency of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from Trentino, North East Italy.

Giuliani S, Leonardi E, Aldovini D, Bernardi D, Pellegrini M, Soli F, Ferro A, Dalla Palma P, Decarli N, Barbareschi M.

Pathologica. 2012 Jun;104(3):93-7.

PMID:
22931039
2.

HPV testing is an efficient management choice for women with inadequate liquid-based cytology in cervical cancer screening.

Giorgi Rossi P, Carozzi F, Collina G, Confortini M, Dalla Palma P, De Lillo M, Del Mistro A, Ghiringhello B, Gillio-Tos A, Maioli P, Pellegrini A, Schiboni ML, Segnan N, Zaffina LM, Zorzi M, Ronco G; NTCC Working Group.

Am J Clin Pathol. 2012 Jul;138(1):65-71. doi: 10.1309/AJCP6J2OEFOYTRFD.

3.

On the diagnostic accuracy of stereotactic vacuum-assisted biopsy of nonpalpable breast abnormalities. Results in a consecutive series of 769 procedures performed at the Trento Department of Breast Diagnosis.

Bernardi D, Borsato G, Pellegrini M, Tuttobene P, Fanto' C, Valentini M, Aldovini D, Ciatto S.

Tumori. 2012 Jan-Feb;98(1):113-8. doi: 10.1700/1053.11509.

4.

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies.

Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D, Bragantini E, Morelli L, Cuorvo LV, Ferro A, Gasperetti F, Berlanda G, Dalla Palma P, Barbareschi M.

Diagn Pathol. 2011 Mar 30;6 Suppl 1:S7. doi: 10.1186/1746-1596-6-S1-S7.

5.

Diagnostic value of automated Her2 evaluation in breast cancer: a study on 272 equivocal (score 2+) Her2 immunoreactive cases using an FDA approved system.

Cantaloni C, Tonini R E, Eccher C, Morelli L, Leonardi E, Bragantini E, Aldovini D, Fasanella S, Ferro A, Cazzolli D, Berlanda G, Dalla Palma P, Barbareschi M.

Appl Immunohistochem Mol Morphol. 2011 Jul;19(4):306-12. doi: 10.1097/PAI.0b013e318205b03a.

PMID:
21293256
6.

Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J; New Technologies for Cervical Cancer screening (NTCC) Working Group.

Lancet Oncol. 2010 Mar;11(3):249-57. doi: 10.1016/S1470-2045(09)70360-2. Epub 2010 Jan 18.

PMID:
20089449
7.

The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study.

Dalla Palma P, Giorgi Rossi P, Collina G, Buccoliero AM, Ghiringhello B, Gilioli E, Onnis GL, Aldovini D, Galanti G, Casadei G, Aldi M, Gomes VV, Giubilato P, Ronco G; NTCC Pathology Group.

Am J Clin Pathol. 2009 Jul;132(1):125-32. doi: 10.1309/AJCPBRK7D1YIUWFP.

8.

Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.

Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, De Marco L, Giorgi-Rossi P, Pontenani G, Rosso S, Sani C, Sintoni C, Segnan N, Zorzi M, Cuzick J, Rizzolo R, Ronco G; New Technologies for Cervival Cancer Screening (NTCC) Working Group.

Lancet Oncol. 2008 Oct;9(10):937-45. doi: 10.1016/S1470-2045(08)70208-0. Epub 2008 Sep 8.

PMID:
18783988
9.

Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P, Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N; New Technologies for Cervical Cancer Screening Working Group.

J Natl Cancer Inst. 2008 Apr 2;100(7):492-501. doi: 10.1093/jnci/djn065. Epub 2008 Mar 25.

10.

The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial.

Dalla Palma P, Giorgi Rossi P, Collina G, Buccoliero AM, Ghiringhello B, Lestani M, Onnis G, Aldovini D, Galanti G, Casadei G, Aldi M, Gomes V, Giubilato P, Ronco G; NTCC Pathology Group.

Am J Clin Pathol. 2008 Jan;129(1):75-80.

11.

M-CAM expression as marker of poor prognosis in epithelial ovarian cancer.

Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, Zeni B, Griso C, Pegoraro C, Zannoni M, Gariboldi M, Balladore E, Mezzanzanica D, Canevari S, Barbareschi M.

Int J Cancer. 2006 Oct 15;119(8):1920-6.

12.

[Tissue microarrays in oncology].

Barbareschi M, Togni R, Aldovini D, Peterlini G, Dal Santo M, Sagramoso C, Dalla Palma P, Lucenti A, Caffo O, Galligioni E, Demichelis F, Sboner A, Dell'Anna R, Di Vizio D, Insabato L, Pettinato G, Mazzoleni G, Macrì E, Doglioni C.

Pathologica. 2003 Oct;95(5):265-6. Italian. No abstract available.

PMID:
14989013
13.

High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.

Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C.

Cancer. 2003 Aug 1;98(3):474-83.

14.

Prognostic value of estrogen receptor status can be improved by combined evaluation of p53, Bcl2 and PgR expression: an immunohistochemical study on breast carcinoma with long-term follow-up.

Mauri FA, Maisonneuve P, Caffo O, Veronese S, Aldovini D, Ferrero S, Cozzaglio F, Dalla Palma P, Galligioni E, Barbareschi M.

Int J Oncol. 1999 Dec;15(6):1137-47.

PMID:
10568820
15.

Differential expression of p57kip2, a maternally imprinted cdk inhibitor, in normal human placenta and gestational trophoblastic disease.

Chilosi M, Piazzola E, Lestani M, Benedetti A, Guasparri I, Granchelli G, Aldovini D, Leonardi E, Pizzolo G, Doglioni C, Menestrina F, Mariuzzi GM.

Lab Invest. 1998 Mar;78(3):269-76.

PMID:
9520940
16.

Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up.

Veronese S, Mauri FA, Caffo O, Scaioli M, Aldovini D, Perrone G, Galligioni E, Doglioni C, Dalla Palma P, Barbareschi M.

Int J Cancer. 1998 Feb 20;79(1):13-8.

17.

Biological characterization of hydatidiform mole by flow cytometry.

Cristofori A, Leonardi E, Aldovini D.

Eur J Histochem. 1997;41 Suppl 2:125-6. No abstract available.

PMID:
9859813
18.

Expression of progesterone receptors in solid-cystic tumour of the pancreas: a clinicopathological and immunohistochemical study of ten cases.

Zamboni G, Bonetti F, Scarpa A, Pelosi G, Doglioni C, Iannucci A, Castelli P, Balercia G, Aldovini D, Bellomi A, et al.

Virchows Arch A Pathol Anat Histopathol. 1993;423(6):425-31.

PMID:
8291215
19.

AgNOR distribution in serous tumours of the ovary.

Mauri FA, Scampini S, Aldovini D, Ferrero S, Barbareschi M, Dalla Palma P.

Pathologica. 1990 Sep-Oct;82(1081):487-92.

PMID:
1706828
20.

[Primary angiosarcoma of the thyroid gland. Presentation of a clinical case].

Neri A, Aldovini D, Leonardi E, Giampiccolo M, Pedrolli C.

Recenti Prog Med. 1990 May;81(5):318-21. Italian.

PMID:
2377809
Items per page

Supplemental Content

Loading ...
Write to the Help Desk